Understanding how KEAP1 mutations affect kidney cancer risk
Official title: Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-10875299 · Data updated 2026-11-12
This study is looking at how changes in a specific gene called KEAP1 might affect kidney cancer, with the hope of finding better ways to screen for and treat this disease, especially for those who may be more likely to get it because of their family history.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $266,666 |
| NIH project number | 5K08CA272960-02 |
| Project ID | NIH-10875299 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of renal cell carcinoma or those diagnosed with RCC at a young age.
✕Less likely to help
Patients with renal cell carcinoma who do not have KEAP1 mutations or a family history of the disease may not benefit from this research.
What this research studies
This research investigates the role of KEAP1 mutations in renal cell carcinoma (RCC), a type of kidney cancer that often has a poor prognosis when diagnosed late. The project aims to identify how these genetic mutations contribute to the development and progression of RCC, which could lead to improved screening and targeted treatment options for patients. The research involves a combination of genetic analysis and clinical assessments to better understand the implications of KEAP1 mutations in cancer susceptibility. By focusing on hereditary aspects of RCC, the study seeks to enhance knowledge about genetic predispositions and their impact on patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to better screening methods and personalized treatment strategies for patients at risk of renal cell carcinoma.
How similar studies have gone: Previous research has shown promising results in understanding genetic mutations in various cancers, suggesting that this approach could yield valuable insights into renal cell carcinoma as well.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Carlo, Maria — Sloan-Kettering Inst Can Research
- Study coordinator: Carlo, Maria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.